$CRDF
Cardiff Oncology, Inc.

2024 Q3 Form 10-Q Financial Statement

#000162828024036098 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $165.0K $163.0K
YoY Change 17.02% 50.93%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.126M $3.215M
YoY Change 6.36% -25.16%
% of Gross Profit
Research & Development $9.640M $9.493M
YoY Change 20.17% 18.37%
% of Gross Profit
Depreciation & Amortization $101.0K $105.0K
YoY Change -8.18% 7.14%
% of Gross Profit
Operating Expenses $12.77M $12.71M
YoY Change 16.47% 3.18%
Operating Profit -$12.60M -$12.55M
YoY Change 16.46% 2.76%
Interest Expense $741.0K $805.0K
YoY Change -30.75% -23.55%
% of Operating Profit
Other Income/Expense, Net $746.0K $767.0K
YoY Change -31.5% -27.5%
Pretax Income -$11.86M -$11.78M
YoY Change 21.84% 5.63%
Income Tax
% Of Pretax Income
Net Earnings -$11.86M -$11.78M
YoY Change 21.83% 5.63%
Net Earnings / Revenue -7184.85% -7225.77%
Basic Earnings Per Share -$0.25 -$0.26
Diluted Earnings Per Share -$0.25 -$0.26
COMMON SHARES
Basic Shares Outstanding 46.55M shares 44.72M shares
Diluted Shares Outstanding 46.87M 44.83M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $48.82M $58.62M
YoY Change -7.77% -3.37%
Cash & Equivalents $13.04M $25.50M
Short-Term Investments $35.79M $33.12M
Other Short-Term Assets $1.047M $1.476M
YoY Change -54.48% -53.02%
Inventory
Prepaid Expenses $1.047M $1.476M
Receivables $618.0K $451.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $59.33M $62.25M
YoY Change -29.29% -32.87%
LONG-TERM ASSETS
Property, Plant & Equipment $993.0K $1.095M
YoY Change -24.6% -19.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.267M $1.271M
YoY Change -8.65% -8.56%
Total Long-Term Assets $3.564M $3.805M
YoY Change -21.62% -19.45%
TOTAL ASSETS
Total Short-Term Assets $59.33M $62.25M
Total Long-Term Assets $3.564M $3.805M
Total Assets $62.90M $66.05M
YoY Change -28.89% -32.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.643M $5.108M
YoY Change 113.08% 73.8%
Accrued Expenses $7.175M $6.712M
YoY Change 16.65% 22.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.53M $12.52M
YoY Change 38.89% 37.26%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $979.0K $1.141M
YoY Change -38.81% -34.91%
Total Long-Term Liabilities $979.0K $1.141M
YoY Change -38.81% -34.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.53M $12.52M
Total Long-Term Liabilities $979.0K $1.141M
Total Liabilities $13.50M $13.66M
YoY Change 27.1% 25.63%
SHAREHOLDERS EQUITY
Retained Earnings -$372.4M -$360.5M
YoY Change 12.78% 12.5%
Common Stock $5.000K $5.000K
YoY Change 25.0% 25.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $49.39M $52.39M
YoY Change
Total Liabilities & Shareholders Equity $62.90M $66.05M
YoY Change -28.89% -32.22%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$11.86M -$11.78M
YoY Change 21.83% 5.63%
Depreciation, Depletion And Amortization $101.0K $105.0K
YoY Change -8.18% 7.14%
Cash From Operating Activities -$10.46M -$9.230M
YoY Change 31.36% 29.42%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$9.434M $14.02M
YoY Change -327.87% 19.43%
Cash From Investing Activities -$9.434M $14.02M
YoY Change -346.96% 22.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.427M 2.058M
YoY Change
NET CHANGE
Cash From Operating Activities -10.46M -9.230M
Cash From Investing Activities -9.434M 14.02M
Cash From Financing Activities 7.427M 2.058M
Net Change In Cash -12.46M 6.843M
YoY Change 201.04% 57.24%
FREE CASH FLOW
Cash From Operating Activities -$10.46M -$9.230M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$10.46M -$9.230M
YoY Change 26.43% 25.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
952-7570
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
CRDF
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25501000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21655000 usd
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
34818000 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
53168000 usd
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
451000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
288000 usd
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1476000 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2301000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
62246000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
77412000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1095000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1238000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1439000 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5108000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1966000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6712000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7783000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
702000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
691000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12522000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10440000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1141000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1458000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
13663000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
11898000 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44825000 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44825000 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44677000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44677000 shares
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
12505000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
919000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
7145000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18651000 usd
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
CARDIFF ONCOLOGY, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-2004382
dei Entity Address Address Line1
EntityAddressAddressLine1
11055 Flintkote Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1708000 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1271000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1279000 usd
CY2024Q2 us-gaap Assets
Assets
66051000 usd
CY2023Q4 us-gaap Assets
Assets
81637000 usd
CY2024Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
277000 shares
CY2023Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
277000 shares
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
61000 shares
CY2024Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
61000 shares
CY2024Q2 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
1080000 usd
CY2023Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
1068000 usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45602000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44677000 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
5000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
413017000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
409343000 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-97000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-67000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-360537000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
52388000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
69739000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66051000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
81637000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
163000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
108000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
368000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
191000 usd
CY2024Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
9493000 usd
CY2023Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8020000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
17501000 usd
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3215000 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4296000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6345000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7379000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
12708000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
12316000 usd
us-gaap Operating Expenses
OperatingExpenses
23846000 usd
us-gaap Operating Expenses
OperatingExpenses
24451000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12545000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12208000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-23478000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-24260000 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-38000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-42000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-106000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
767000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1058000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1689000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1887000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-11778000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11150000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21789000 usd
us-gaap Net Income Loss
NetIncomeLoss
-22373000 usd
CY2024Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6000 usd
CY2023Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6000 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
12000 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
12000 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11784000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11156000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21801000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22385000 usd
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-11778000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11150000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21789000 usd
us-gaap Net Income Loss
NetIncomeLoss
-22373000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-355000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-30000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-36000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11743000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11505000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21819000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22409000 usd
CY2024Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6000 usd
CY2023Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6000 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
12000 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
12000 usd
CY2023Q2 crdf Comprehensive Income Loss Available To Common Stockholders Basic
ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
-11511000 usd
crdf Comprehensive Income Loss Available To Common Stockholders Basic
ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
-21831000 usd
crdf Comprehensive Income Loss Available To Common Stockholders Basic
ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
-22421000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
69739000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
35000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-11778000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
52388000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
106343000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1064000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
319000 usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
46549634 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44677000 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001213037
CY2024Q1 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2024#AccountingStandardsUpdate202006Member
dei Document Type
DocumentType
10-Q
dei Entity File Number
EntityFileNumber
001-35558
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45602000 shares
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-339541000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
17072000 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
805000 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1053000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1731000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1993000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44752000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44752000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44677000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44677000 shares
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
35000 usd
CY2024Q2 crdf Comprehensive Income Loss Available To Common Stockholders Basic
ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
-11749000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1124000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
107000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-65000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-10011000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
60894000 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1805000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1179000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
253000 usd
CY2024Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
197000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11223000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
96503000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1581000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-355000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11150000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
86579000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21789000 usd
us-gaap Net Income Loss
NetIncomeLoss
-22373000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
207000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
188000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2303000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2645000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
283000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
405000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
163000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-610000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-696000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2260000 usd
crdf Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-269000 usd
crdf Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-273000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-8000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
3000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2088000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1293000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-306000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-279000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16970000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15791000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
80000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
259000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
68265000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
50868000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
1675000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18813000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
197000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1805000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
360000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2165000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3846000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3022000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21655000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16347000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25501000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19369000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
16000 usd
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
60300000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11159352 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9412486 shares
CY2024Q2 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
33224000 usd
CY2024Q2 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
10000 usd
CY2024Q2 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
111000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
33123000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
1690000 usd
CY2024Q2 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
5000 usd
CY2024Q2 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
0 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
1695000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
34914000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
15000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
111000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
34818000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
26293000 usd
CY2023Q4 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
33000 usd
CY2023Q4 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
17000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
26309000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
26942000 usd
CY2023Q4 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
6000 usd
CY2023Q4 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
89000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
26859000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
53235000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
39000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
106000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
53168000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
14127000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
91000 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5049000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4990000 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3954000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3752000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1095000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1238000 usd
CY2024Q2 crdf Accrued Clinical Trial
AccruedClinicalTrial
3832000 usd
CY2023Q4 crdf Accrued Clinical Trial
AccruedClinicalTrial
4309000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1790000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2737000 usd
CY2024Q2 crdf Accrued Research Agreements
AccruedResearchAgreements
867000 usd
CY2023Q4 crdf Accrued Research Agreements
AccruedResearchAgreements
530000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
223000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
207000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6712000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7783000 usd
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1179000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1581000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2303000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2645000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2700000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3200000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
8150000 shares
CY2024Q2 us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
1697712 shares
CY2024Q2 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
3.51
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1697712 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.51
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2807948 shares
CY2023Q4 crdf Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
2.45
CY2024Q1 crdf Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights
ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
P1Y10M24D
CY2024Q2 crdf Class Of Warrant Or Right Expired During Period
ClassOfWarrantOrRightExpiredDuringPeriod
595 shares
CY2024Q2 crdf Class Of Warrant Or Right Weighted Average Exercise Price Expired During Period
ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod
252.72
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2807353 shares
CY2024Q2 crdf Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
2.40
crdf Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights
ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
P1Y4M24D
CY2024Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1800000 usd
CY2024Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
800000 shares
crdf Collaborative Arrangement Rights And Obligations Milestone And Royalty Payments Made
CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade
0 usd
crdf Collaborative Arrangement Rights And Obligations Milestone And Royalty Payments Made
CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade
0 usd

Files In Submission

Name View Source Status
0001628280-24-036098-index-headers.html Edgar Link pending
0001628280-24-036098-index.html Edgar Link pending
0001628280-24-036098.txt Edgar Link pending
0001628280-24-036098-xbrl.zip Edgar Link pending
crdf-063024exhibit311.htm Edgar Link pending
crdf-063024exhibit312.htm Edgar Link pending
crdf-063024exhibit321.htm Edgar Link pending
crdf-063024exhibit322.htm Edgar Link pending
crdf-20240630.htm Edgar Link pending
crdf-20240630.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
crdf-20240630_cal.xml Edgar Link unprocessable
crdf-20240630_def.xml Edgar Link unprocessable
crdf-20240630_lab.xml Edgar Link unprocessable
crdf-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
crdf-20240630_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending